BR112017018649B8 - Composto bicíclico de piridina - Google Patents
Composto bicíclico de piridinaInfo
- Publication number
- BR112017018649B8 BR112017018649B8 BR112017018649A BR112017018649A BR112017018649B8 BR 112017018649 B8 BR112017018649 B8 BR 112017018649B8 BR 112017018649 A BR112017018649 A BR 112017018649A BR 112017018649 A BR112017018649 A BR 112017018649A BR 112017018649 B8 BR112017018649 B8 BR 112017018649B8
- Authority
- BR
- Brazil
- Prior art keywords
- lap
- inventors
- avp
- bicyclic
- inhibition
- Prior art date
Links
- -1 Bicyclic Pyridine Compound Chemical class 0.000 title abstract 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 230000002686 anti-diuretic effect Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 206010029446 nocturia Diseases 0.000 abstract 2
- 230000000422 nocturnal effect Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000004400 Aminopeptidases Human genes 0.000 abstract 1
- 108090000915 Aminopeptidases Proteins 0.000 abstract 1
- 108091000069 Cystinyl Aminopeptidase Proteins 0.000 abstract 1
- 102100020872 Leucyl-cystinyl aminopeptidase Human genes 0.000 abstract 1
- 241000700159 Rattus Species 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
composto bicíclico de piridina.o problema a ser resolvido pela presente invenção é fornecer um composto adequado para uma composição farmacêutica, especificamente uma composição farmacêutica para o tratamento de noctúria. os inventores têm assumido que a inibição da atividade noturna de leucina aminopeptidase placentária (p-lap), ou seja, amino-peptidase que cliva a avp, manteria e/ou aumentaria um nível endógeno de avp para aprimorar o efeito antidiurético, que contribuiria para uma diminuição do número de esvaziamentos noturnos e têm extensivamente estudado compostos que inibem a p-lap. como resultado, os inventores descobriram que os derivados de ácido (2r)-3-amino-2-(piridilmetil bicíclico)-2-hidróxi-propanoico têm excelente atividade inibitória da p-lap. os inventores têm avaliado os efeitos antidiuréticos em ratos carregados de água e descobriram que os compostos aumentam os níveis de avp endógena por inibir p-lap e consequentemente reduzem a produção de urina. a presente invenção fornece, portanto, compostos esperados por serem usados como um agente para o tratamento de noctúria baseado na inibição de p-lap.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015-046121 | 2015-03-09 | ||
| JP2015046121 | 2015-03-09 | ||
| PCT/JP2015/083345 WO2016143200A1 (ja) | 2015-03-09 | 2015-11-27 | 二環式ピリジン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112017018649A2 BR112017018649A2 (pt) | 2018-04-17 |
| BR112017018649B1 BR112017018649B1 (pt) | 2023-07-11 |
| BR112017018649B8 true BR112017018649B8 (pt) | 2023-10-03 |
Family
ID=56880128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017018649A BR112017018649B8 (pt) | 2015-03-09 | 2015-11-27 | Composto bicíclico de piridina |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10023583B2 (pt) |
| EP (1) | EP3269721B1 (pt) |
| JP (1) | JP6646648B2 (pt) |
| KR (1) | KR102446212B1 (pt) |
| CN (1) | CN107428768B (pt) |
| AR (1) | AR102849A1 (pt) |
| AU (1) | AU2015386039B2 (pt) |
| BR (1) | BR112017018649B8 (pt) |
| CA (1) | CA2976746C (pt) |
| CO (1) | CO2017008372A2 (pt) |
| ES (1) | ES2869924T3 (pt) |
| IL (1) | IL254307B (pt) |
| MX (1) | MX370920B (pt) |
| MY (1) | MY198083A (pt) |
| PH (1) | PH12017501596B1 (pt) |
| PL (1) | PL3269721T3 (pt) |
| PT (1) | PT3269721T (pt) |
| RU (1) | RU2700411C2 (pt) |
| SG (1) | SG11201706745PA (pt) |
| TW (1) | TWI700285B (pt) |
| UA (1) | UA121889C2 (pt) |
| WO (1) | WO2016143200A1 (pt) |
| ZA (1) | ZA201706038B (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020080394A1 (ja) | 2018-10-16 | 2020-04-23 | 日本ケミファ株式会社 | 睡眠の質の改善剤 |
| US20210393562A1 (en) | 2018-10-17 | 2021-12-23 | Nippon Chemiphar Co., Ltd. | Therapeutic or prophylactic agent for nocturnal polyuria |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200702041B (en) | 2004-09-09 | 2008-09-25 | Florey Howard Inst | Enzyme inhibitors and uses thereof |
| JP5198439B2 (ja) * | 2006-06-08 | 2013-05-15 | イーライ リリー アンド カンパニー | 新規なｍｃｈ受容体アンタゴニスト |
| NZ585338A (en) | 2007-11-19 | 2012-08-31 | Howard Florey Inst | Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof |
| CA2741500A1 (en) | 2008-11-06 | 2010-05-14 | Astellas Pharma Inc. | Carbamate compound or salt thereof |
| JP2013147430A (ja) * | 2010-04-28 | 2013-08-01 | Astellas Pharma Inc | 夜間頻尿の予防又は治療剤 |
| SI2615089T1 (sl) * | 2010-09-07 | 2016-08-31 | Astellas Pharma Inc. | Spojine pirazolokinolina |
| IN2015DN00127A (pt) * | 2012-07-11 | 2015-05-29 | Nimbus Iris Inc | |
| TWI647227B (zh) | 2013-02-28 | 2019-01-11 | 日商安斯泰來製藥股份有限公司 | ２－醯胺噻唑衍生物或其鹽 |
| RU2683261C2 (ru) * | 2014-05-28 | 2019-03-27 | Астеллас Фарма Инк. | Производное пиридина |
-
2015
- 2015-11-26 AR ARP150103899A patent/AR102849A1/es unknown
- 2015-11-27 PL PL15884684T patent/PL3269721T3/pl unknown
- 2015-11-27 SG SG11201706745PA patent/SG11201706745PA/en unknown
- 2015-11-27 TW TW104139686A patent/TWI700285B/zh active
- 2015-11-27 US US15/551,222 patent/US10023583B2/en active Active
- 2015-11-27 ES ES15884684T patent/ES2869924T3/es active Active
- 2015-11-27 BR BR112017018649A patent/BR112017018649B8/pt active IP Right Grant
- 2015-11-27 MY MYPI2017703298A patent/MY198083A/en unknown
- 2015-11-27 CA CA2976746A patent/CA2976746C/en active Active
- 2015-11-27 PT PT158846840T patent/PT3269721T/pt unknown
- 2015-11-27 MX MX2017010930A patent/MX370920B/es active IP Right Grant
- 2015-11-27 KR KR1020177020910A patent/KR102446212B1/ko active IP Right Grant
- 2015-11-27 AU AU2015386039A patent/AU2015386039B2/en active Active
- 2015-11-27 UA UAA201709737A patent/UA121889C2/uk unknown
- 2015-11-27 EP EP15884684.0A patent/EP3269721B1/en active Active
- 2015-11-27 CN CN201580077585.XA patent/CN107428768B/zh active Active
- 2015-11-27 RU RU2017134316A patent/RU2700411C2/ru active
- 2015-11-27 WO PCT/JP2015/083345 patent/WO2016143200A1/ja active Application Filing
- 2015-11-27 JP JP2017504564A patent/JP6646648B2/ja active Active
-
2017
- 2017-08-16 CO CONC2017/0008372A patent/CO2017008372A2/es unknown
- 2017-09-04 IL IL254307A patent/IL254307B/en active IP Right Grant
- 2017-09-05 ZA ZA2017/06038A patent/ZA201706038B/en unknown
- 2017-09-05 PH PH12017501596A patent/PH12017501596B1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
| BR112015021999A2 (pt) | inibidores de indoleamina 2,3-dioxigenase (ido) | |
| BR112015022462A2 (pt) | inibidores de ido | |
| BR112015032595A8 (pt) | inibidores de ido | |
| BR112017020999A2 (pt) | inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer | |
| MX2016000295A (es) | Inhibidores de indoleamina 2,3-dioxigenasa (ido). | |
| EA201791018A1 (ru) | Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы | |
| BR112016015706A8 (pt) | composto, uso do mesmo e composição farmacêutica | |
| EA201691590A1 (ru) | Бензимидазол-2-амины в качестве ингибиторов midhi | |
| GEP20217316B (en) | Aromatic sulfonamide derivatives | |
| MX2016002075A (es) | Inhibidores de indolamina 2,3-dioxigenasa (ido). | |
| EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
| BR112016014481A2 (pt) | tratamento de câncer utilizando combinações de inibidores de erk e raf | |
| EA201792028A1 (ru) | Альфа-цинамидные соединения и композиции как ингибиторы hdac8 | |
| EA201591727A1 (ru) | Соединения биариламида в качестве ингибиторов киназы | |
| EA201691461A1 (ru) | Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения | |
| PH12017500841A1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| BR112014028042A2 (pt) | inibidores de nampt | |
| MX2016014911A (es) | Acidos hidroxamicos heterociclicos como inhibidores de proteina desacetilasa e inhibidores dobles de proteina desacetilasa-proteina cinasa, y metodos de uso de los mismos. | |
| MX2019006863A (es) | Inhibidores de heparanasa y uso de los mismos. | |
| EA201791933A1 (ru) | Ингибирование активности olig2 | |
| EA202091003A1 (ru) | Новые производные пиразолопирролопиримидиндиона в качестве ингибиторов p2x3 | |
| EA201990508A1 (ru) | ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2 | |
| BR112017018649B8 (pt) | Composto bicíclico de piridina | |
| BR112016027729A2 (pt) | Composto derivado de piridina, composição farmacêutica contendo o referido composto e seu uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/11/2015, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2740 DE 11/07/2023 QUANTO AO ENDERECO POR ERRO MATERIAL DO TITULAR. |